Vaxart to Present at World Vaccine Congress Washington 2024 on April 3

PDF Version SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at t

VaxartMar 27 12:00

Press Release: Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") tod

Dow JonesMar 20 20:00

Buy Rating Affirmed for Vaxart Amid Promising Vaccine Trials and Strategic Advancements

TipRanksMar 20 19:25

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PDF Version SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that the Compensation Committee of the Board of D

VaxartMar 20 12:00

Estimating The Intrinsic Value Of Vaxart, Inc. (NASDAQ:VXRT)

Yahoo FinanceMar 17 22:41

Earnings Call Summary | Vaxart(VXRT.US) Q4 2023 Earnings Conference

The following is a summary of the Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript:Financial Performance:Vaxart reported a revenue of $7.4 million in 2023, an increase compared to $0.1 million in

Futu NewsMar 15 07:37 · Conference Call